Methods for determining drug efficacy using cereblon-associated proteins

Abstract

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

Description

1 CLAIM OF PRIORITY[0001]This application is a divisional of U.S. application Ser. No. 13 / 931,642, filed on Jun. 28, 2013, which claims the benefit of priority to U.S. Provisional Application No. 61 / 696,752, filed on Sep. 4, 2012 and U.S. Provisional Application No. 61 / 666,703, filed Jun. 29, 2012, the content of each of which is incorporated by reference herein in its entirety.2 FIELD[0002]Provided herein are methods of determining the efficacy of an immunomodulatory compound. Also provided herein are methods of using cereblon-associated proteins as biomarkers for clinical sensitivity to cancer and inflammatory diseases, and patient response to drugs. Further provided are kits for carrying out the methods.3 BACKGROUND[0003]3.1 Pathobiology of Cancer[0004]Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, or lymphatic or blood-borne spread of malignant cells to reg...

AI Technical Summary

Benefits of technology

The patent describes methods for determining whether a compound is immunomodulatory, meaning it can affect the immune system. The methods involve contacting cells with the compound and measuring the level of a protein called CRBN-associated protein. This protein is associated with the immunomodulatory activity of the compound. The methods can be performed in vitro or in vivo, and can be used to assess the efficacy of the compound in treating diseases such as cancer or inflammatory diseases. The patent also describes a method for measuring the level of CRBN-associated protein in a sample obtained from a tumor biopsy or other sources.

Problems solved by technology

However, options for the treatment of cancer are limited.

For example, in the case of blood cancers (e.g., multiple myeloma), few treatment options are available, especially when conventional chemotherapy fails and bone-marrow transplantation is not an option.

Although viruses reportedly cause several forms of leukemia in animals, causes of leukemia in humans are to a large extent unknown.

However, uncontrolled growth of these cells leads to bone pain and fractures, anemia, infections, and other complications.

MDS is characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis), peripheral blood cytopenias, and a variable risk of progression to acute leukemia, resulting from ineffective blood cell production.

The approach for patients with relapsed or refractory disease relies heavily on experimental treatments followed by stem cell transplantation, which may not be appropriate for patients with a poor performance status or advanced age.

Thus, inhibition of HIF1 may slow or reverse tumor cell metabolism.

These events result in swelling, redness, warmth (altered heat patterns), and pus formation at the site of injury or infection.

This release of cytokines and prostaglandins increases the blood flow to the area of injury or infection, and may result in redness and warmth.

Some of these chemicals cause a leak of fluid into the tissues, resulting in swelling.

This protective process may stimulate nerves and cause pain.

When this delicately balanced interplay is disrupted, the inflammatory response may result in considerable damage to normal tissue and may be more harmful than the original insult that initiated the reaction.

These cellular tests are cumbersome and often require the use of various stimulants (e.g., lipopolysaccharide or anti-CD3 antibody).

Further, clinical efficacy of these compounds could not be correctly predicted, as it could only be measured in terms of patient response, which usually requires a minimum of several months of treatment.

Images